Compare Gilead Sciences, Inc. (GILD) vs Select Medical Holdings Corporation (SEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Select Medical Holdings Corporation — how do they compare? Gilead Sciences, Inc. trades at $135.5 (market cap $163.51B), while Select Medical Holdings Corporation trades at $16.51 (market cap $2.05B). The key difference: Gilead Sciences, Inc. is far larger — about 79.8× Select Medical Holdings Corporation's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| GILD | SEM | |
|---|---|---|
Market Cap | $163.51B | $2.05B |
Sector | Health | Health |
52-Week High | $155.80 | $16.66 |
52-Week Low | $108.22 | $11.77 |
Enterprise Value | $178.05B | $5.01B |
Dividend Yield | 2.49% | 1.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Select Medical Holdings Corporation (SEM) trades at $16.51, unchanged on the day. The stock's technical outlook is mixed with a bullish overall signal but bearish moving averages. Fundamentally, the company reported 2025 revenue of $5.45 billion and net income of $146.22 million, with a P/E ratio of 15.43. Recent news highlights the completion of its acquisition by a consortium led by Robert A. Ortenzio and Martin F. for $16.50 per share, finalized on June 30, 2026.
The acquisition at $16.50 per share, slightly below the current price, represents a key near-term catalyst but is under legal scrutiny for potential fiduciary breaches. Analyst sentiment is cautious with a 'Hold' consensus. Risks include integration challenges post-acquisition and margin pressures, with net profit margin declining to 2.41% in 2026. The stock offers limited upside from current levels given the acquisition price cap.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Select Medical Holdings Corporation
Select Medical Holdings Corporation is one of the largest operators of critical illness recovery hospitals, rehabilitation hospitals, outpatient rehabilitation clinics, and occupational health centers in the United States. The company's services focus on treating patients with serious illnesses, injuries, and post-acute care needs. SEM provides specialized care across various settings, aiming to help patients recover and return home.
Read more on SEM →
